These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 4167083)

  • 21. [Assessment of clinical usefulness of Eviprostat for benign prostatic hyperplasia--comparison of Eviprostat tablet with a formulation containing two-times more active ingredients].
    Tamaki M; Nakashima M; Nishiyama R; Ikeda H; Hiura M; Kanaoka T; Nakano T; Hayashi T; Ogawa O
    Hinyokika Kiyo; 2008 Jun; 54(6):435-45. PubMed ID: 18634442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical experiences with phyto-therapy of benign prostatic hypertrophy].
    Bauer KM
    Med Welt; 1980 Aug; 31(34):1211-4. PubMed ID: 6159518
    [No Abstract]   [Full Text] [Related]  

  • 23. [Use of Eviprostat for treatment of prostatic hypertrophy].
    Ookita K; Shiraga T; Matsumura Y
    Hinyokika Kiyo; 1966 May; 12(5):511-7. PubMed ID: 4164092
    [No Abstract]   [Full Text] [Related]  

  • 24. [Conservative therapy of prostatic adenoma as well as prostatitis with beta-sitosterol prostate capsules].
    Karcher G
    Med Welt; 1982 Dec; 33(48):1763-6. PubMed ID: 6185822
    [No Abstract]   [Full Text] [Related]  

  • 25. [Use of a preparation with pollen extract base in patients with prostatic hypertrophy].
    Inada T; Kitagawa T; Miyakawa M
    Clin Ter; 1970 Jun; 53(5):431-8. PubMed ID: 4097408
    [No Abstract]   [Full Text] [Related]  

  • 26. [Evaluation report on spasmo-urgenin. A new urospasmolytic].
    Schöll H; Reinhofer E
    Med Welt; 1971 Mar; 12():471-3. PubMed ID: 4104508
    [No Abstract]   [Full Text] [Related]  

  • 27. [Evaluation of supplemental administration of Eviprostat in patients with benign prostatic hyperplasia with persistent symptoms following treatment with alpha1-adrenoceptor blocker].
    Naruoka T; Suzuki Y; Furuta A; Endo K; Sugaya S; Egawa S
    Hinyokika Kiyo; 2008 May; 54(5):341-4. PubMed ID: 18546857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and retrospective evaluation of Eviprostat: a non-hormonal and non-neuropharmacological agent for benign prostatic hyperplasia.
    Ishigooka M; Hashimoto T; Hayami S; Tomaru M; Nakada T; Mitobe K
    Int Urol Nephrol; 1995; 27(1):61-6. PubMed ID: 7542229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protective effect of Prostane in experimental prostatic hyperplasia in rats.
    Mitra SK; Sundaram R; Mohan AR; Gopumadhavan S; Venkataranganna MV; Venkatesha U; Seshadri SJ; Anturlikar SD
    Asian J Androl; 1999 Dec; 1(4):175-9. PubMed ID: 11225890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Vitaprost forte efficacy in patients with prostatic adenoma].
    Tkachuk VN; Tkachuk IN
    Urologiia; 2008; (4):34-7. PubMed ID: 19058362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical effects of chlormadinone acetate (Prostal) on patients with prostatic hypertrophy--with reference to estimation of size and weight of prostate by means of transrectal ultrasonotomography].
    Yoshida H; Haraguchi C; Ogawa Y; Kawai N; Ohyama M; Higaki Y; Saitoh T; Imamura K
    Hinyokika Kiyo; 1983 Nov; 29(11):1419-26. PubMed ID: 6203377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [On the use of a new drug in the therapy of prostatic adenoma: Tadenan. Clinical considerations on 23 cases].
    Durval A
    Minerva Urol; 1970; 22(3):106-11. PubMed ID: 4099512
    [No Abstract]   [Full Text] [Related]  

  • 33. [Contribution to the treatment of irritative manifestations of the bladder].
    Rusch G
    Praxis; 1967 Aug; 56(34):1167-70. PubMed ID: 4174716
    [No Abstract]   [Full Text] [Related]  

  • 34. [Treatment of spastic complications in prostate and bladder diseases with Spasmo-Urgenin].
    Hartung F; Massier J
    Med Welt; 1968 May; 19():1262-3. PubMed ID: 4181968
    [No Abstract]   [Full Text] [Related]  

  • 35. [Regression of the symptoms of prostatic adenomas. Results of 6 months' conservative treatment using ERU capsules].
    Maar K
    Fortschr Med; 1987 Jan; 105(1):18-20. PubMed ID: 2435642
    [No Abstract]   [Full Text] [Related]  

  • 36. [Conservative therapy of prostatic hyperplasia with urinary retention].
    Djulepa J
    Med Welt; 1983 Dec; 34(48):1377-9. PubMed ID: 6197601
    [No Abstract]   [Full Text] [Related]  

  • 37. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia.
    Kaplan SA
    J Urol; 2005 Sep; 174(3):1011. PubMed ID: 16094031
    [No Abstract]   [Full Text] [Related]  

  • 38. [Clinical experimentation with V 1326 in prostatic disorders].
    Lange ; Muret
    Bord Med; 1970 Nov; 3(11):2807-8 passim. PubMed ID: 4101700
    [No Abstract]   [Full Text] [Related]  

  • 39. [Treatment of prostatitis with doxycycline].
    Oosterlinck W; Wijndaele JJ
    Nouv Presse Med; 1980 Jan; 9(21 Suppl):128-30. PubMed ID: 6153464
    [No Abstract]   [Full Text] [Related]  

  • 40. [Clinical use of eviprostat for hypertrophy of prostate].
    Inada T; Sakatoku J; Ebisuta K; Kitayama T
    Hinyokika Kiyo; 1966 Apr; 12(4):403-9. PubMed ID: 4163784
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.